Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Adjuvant Therapy
17%
Biopsy Technique
7%
Breast Cancer
6%
Cancer Treatment
11%
Chemotherapy
5%
Clinical Trial
6%
Diseases
14%
Fine-Needle Aspiration
5%
Hazard Ratio
7%
Immunotherapy
13%
In-Transit Metastasis
5%
Interferon
8%
Ipilimumab
9%
Isolation Perfusion
5%
Limb
13%
Limb Perfusion
29%
Liver Metastasis
6%
Lymph Node
5%
Malignant Neoplasm
18%
Melanoma
100%
Melanoma Skin Cancer
11%
Melphalan
24%
Metastatic Carcinoma
11%
Metastatic Melanoma
9%
Neoplasm
20%
Oncology
7%
Overall Survival
13%
Pembrolizumab
10%
Phase III Trials
6%
Placebo
10%
Prognostic Factor
10%
Radiation Therapy
5%
Rectum Cancer
5%
Recurrence Free Survival
9%
Recurrent Disease
12%
Retroperitoneal Lymph Node Dissection
10%
Sentinel Lymph Node Biopsy
5%
Sentinel Node
19%
Soft Tissue Sarcoma
11%
Tumor
21%
Tumor Necrosis Factor
21%
Keyphrases
Adjuvant Therapy
11%
Advanced Melanoma
5%
Cancer Therapy
5%
Cancer Treatment
11%
Chemotherapy
6%
EORTC
12%
European Organizations
10%
Extremity Soft Tissue Sarcoma
5%
Hazard Ratio
6%
High Dose
5%
High Risk
6%
In Cancer
6%
In-transit Metastasis
5%
Interferon-α (IFN-α)
13%
Interleukin-2
7%
Ipilimumab
5%
Isolated Limb Perfusion
29%
Isolated Perfusion
5%
Malignant Melanoma
6%
Melanoma
48%
Melanoma Patients
15%
Melphalan
22%
Metastatic Melanoma
7%
Overall Survival
8%
Pembrolizumab
8%
Perfusion
9%
Placebo
8%
Primary Melanoma
6%
Prognostic Factors
5%
Randomized Phase III Trial
6%
Recurrence-free Survival
5%
Sarcoma
5%
Sentinel Lymph Node
8%
Sentinel Lymph Node Biopsy
9%
Soft Tissue Sarcoma
5%
Stage III Melanoma
13%
Tumor
18%
Tumor Necrosis Factor-α
30%
Tumor Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
7%
Clinical Trial
5%
Diseases
6%
Doxorubicin
7%
Hyperthermia
5%
Immunotherapy
11%
Interferon
9%
Interleukin 2
5%
Ipilimumab
6%
Limb Perfusion
13%
Liposome
8%
Malignant Neoplasm
29%
Melanoma
47%
Melphalan
11%
Metastatic Melanoma
5%
Neoplasm
22%
Overall Survival
6%
Phase III Trials
5%
Placebo
5%
Rat
15%
Recurrence Free Survival
6%
Soft Tissue Sarcoma
5%
Solid Malignant Neoplasm
5%
Tumor Necrosis Factor
17%
